

**INVENTOR:** Vladka Curin-Serbec

**DOCKET NO.: 201196/50**

**D** **E** **F** **G** **H** **I** **J** **K** **L** **M**

5

**Antibodies capable to selectively detect prion PrP<sup>Sc</sup> isoforms**

10

The present invention pertains to novel antibodies directed to the C-terminal part of the PrP<sup>Sc</sup> isoform of prions. In particular, the present invention pertains to the use of such antibodies in the diagnosis of bovine spongiform encephalopathy (BSE), the new variant form of Creutzfeldt Jacobs Disease (vCJD), sporadic CJD and scrapie.

15

Starting in 1986 a chronic degenerative disease has been diagnosed in the United Kingdom. Cattle affected by this disease experienced progressive degeneration of the nervous system, displayed changes in temperament, such as nervousness or aggression, abnormal posture, incoordination and difficulty in rising, decreased milk production, or loss of body weight despite continued appetite. The affected cattle eventually died.

20

This disease had been termed Bovine Spongiform Encephalopathy (BSE) and is now widely referred to as "mad cow disease". During the following ten years approximately 160 000 cases of this newly-recognized cattle disease were confirmed in the United Kingdom, while also in other European countries and even in countries abroad, e.g. Canada, The Falkland islands and the Oman Sultanate animals suffering from said disease were reported.

25

BSE is associated with a transmissible agent, the nature of which is not yet fully understood. The agent affects the brain and spinal cord of cattle and lesions are characterized by sponge-like changes visible by means of a microscope. This agent is highly stable, and withstands heating to normal cooking temperatures and to even higher temperatures such as those used for pasteurization, sterilization at usual temperatures and time periods, as well as to freezing and drying.

30

In cattle naturally infected with BSE, the BSE agent has been found only in brain tissue, in the spinal cord, and in the retina. Additional studies have identified BSE infectivity in the distal ileum, bone marrow, dorsal root ganglion, and trigeminal ganglion of calves that had been fed brain material from BSE-infected animals.

5 In human beings a similar degenerative syndrome is known, which is termed Creutzfeld-Jacobs disease (CJD). CJD is a slow degenerative human disease of the central nervous system with obvious dysfunction, progressive dementia, and vacuolar degeneration of the brain. CJD occurs sporadically worldwide at a rate of 1 case per 1 million people per year. 10 More rare are the related TSE (Transmissible Spongiform Encephalopathy) conditions of the Gerstmann- Straussler syndrome, kuru and fatal familial insomnia.

15 In 1996, the UK's Spongiform Encephalopathy Advisory Committee (SEAC) announced the identification of 10 cases of a new variant form of CJD (vCJD). All of the patients developed onset of illness in 1994 or 1995. However, the 10 cases reported vastly differed from the sporadic form of CJD. The affected individuals were much younger than the classical CJD patient. Typically, CJD patients are over 63 years old. In contrast thereto, the average patient's age for the onset of variant CJD was about 28. The course of the disease in the vCJD averaged 13 months which differs from classical CJD cases, which average a 6 month 20 duration. In the variant cases, electroencephalographic (EEG) electrical activity in the brain was not typical of sporadic CJD. Although brain pathology was recognizable as CJD, the pattern was different from sporadic CJD, with large aggregates of prion protein plaques.

25 According to the SEAC, all victims were reported to have eaten beef or beef products in the last 10 years, indicating a causative relationship between vCJD and BSE. Two studies published in 1997 confirmed the assumption that the BSE agent is highly likely to be the cause of vCJD. To this end, a group of researcher infected three panels of inbred mice and one panel of crossbred mice with BSE, vCJD and sporadic CJD, respectively. Interim results indicated that mice inoculated with BSE showed the same pattern of incubation time, clinical 30 signs and brain lesions as mice inoculated with tissues from patients with vCJD from which

0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840

20

25

30

extremely resistant to heat and to normal sterilization processes. It also does not evoke any detectable immune response or inflammatory reaction in host animals.

In the recent past it has now been found that the agent responsible for the disease is distinct from viruses. The agent can exist in multiple molecular forms, whereas viruses exist in a single form with distinct ultrastructural morphology. Second, these agents are non-immunogenic, in contrast to viruses, which almost always provoke an immune response. Third, there is no evidence for an essential nucleic acid within the infectious particle, whereas viruses have a nucleic acid genome which serves as the template for the synthesis of progeny virus. Thus, it was eventually concluded that prions are the cause for the degenerative disease, the only known component thereof is the prion, which is encoded by a chromosomal gene of the individual itself.

Infectious prions are essentially composed of a protein designated as the "scarpie isoform" of the prion protein, abbreviated as  $\text{PrP}^{\text{Sc}}$ . A post-translational process, as yet undefined, obviously generates  $\text{PrP}^{\text{Sc}}$  from the ubiquitous cellular prion protein  $\text{PrP}^{\text{C}}$ . Both,  $\text{PrP}^{\text{Sc}}$  and  $\text{PrP}^{\text{C}}$  are encoded by a single copy chromosomal gene and it has been shown that the inoculated prion initiates the production of  $\text{PrP}^{\text{Sc}}$  from the normal host  $\text{PrP}^{\text{C}}$  polypeptide. In contrast to the normal form, which is mainly found on the cell surface the isoforms are accumulated within the cells in vesicles. The isoforms also differ in their conformational structure, exhibited by an increased  $\beta$ -sheet content which might be a cause for the increased protease resistance of the  $\text{PrP}^{\text{Sc}}$  isoform versus the normal form  $\text{PrP}^{\text{C}}$ .

At present there is no treatment nor any vaccine available to prevent the disease. This may be mainly due to the obvious low immunogenicity of the  $\text{PrP}^{\text{Sc}}$  isoform which has prevented the manufacture of antibodies specifically recognizing the  $\text{PrP}^{\text{Sc}}$  isoform, while simultaneously avoiding cross-reactivity with the "normal" isoform,  $\text{PrP}^{\text{C}}$ .

Moreover, there is also no adequate test to detect the disease in a live animal. Veterinary pathologists may confirm BSE by postmortem microscopic examination of brain tissue. Yet,

when it comes to detect the presence of the BSE agent in tissues this is determined by inoculating animals, usually mice, with material believed to be infected with BSE. Thus, there exists a need in the art to provide a means with which the agents responsible for the development of degenerative diseases of the nervous system, such as BSE, CJD, vCJD or TSE related diseases, like scrapie and others.

The problem of the present invention therefore resides in providing means, which enables a veterinary and/or physician to specifically detect the presence of agents causing BSE, CJD, vCJD and/or TSE related diseases.

In the course of the extensive studies leading to the invention the present inventors have found that one of the conformational changes, the PrP<sup>C</sup> undergoes in its transformation to PrP<sup>Sc</sup> resides in a modification of the tertiary structure of the C-terminal region of PrP<sup>C</sup>.

In the figures,

Fig. 1 shows a picture (10 times enlarged) of a human brain tissue sample derived from an individuum subject to sporadic CJD treated with the antibody CNCM I-2476.

Fig. 2 shows a picture (60 times enlarged) of a human brain tissue sample derived from an individuum subject to sporadic CJD treated with the antibody CNCM I-2476.

Fig. 3 shows a picture (60 times enlarged) of a human brain tissue sample derived from an individuum subject to new variant CJD treated with the antibody CNCM I-2476.

Fig. 4 shows a picture (20 times enlarged) of a human brain tissue sample derived from an individuum subject to new variant CJD treated with the antibody CNCM I-2476.

Fig. 5 shows a picture (20 times enlarged) of a bovine brain tissue sample derived from an animal exhibiting signs of BSE treated with the antibody CNCM I-2476.

Fig. 6 shows a picture (10 times enlarged) of a brain tissue sample derived from a goat subject to scrapie treated with the antibody CNCM I-2476.

5 ~~Fig. 7 shows the results of a Dot Blot experiment, wherein various samples of normal brain~~  
~~tissues are exposed to the antibody CNCM I-2476. As a control the peptide of Seq. ID. No. 2~~  
~~and the conjugate of said peptide and KLH was used.~~

Thus, according to an embodiment the present invention provides for an antibody directed to  
 the C-terminal part of the PrP<sup>Sc</sup> isoform or a part thereof, that is, to a three dimensional  
 conformation of said part of the prion polypeptide exhibited in the "misfolded" form. Since  
 the PrP<sup>C</sup> form does exhibit a three dimensional conformation in this part of the prion  
 polypeptide obviously different from PrP<sup>Sc</sup> the present antibodies are capable to selectively  
 bind to the PrP<sup>Sc</sup> isoform while not binding to the PrP<sup>C</sup> form. They are therefore capable to  
 distinguish between those isoforms. The antibodies are preferably directed to the region  
 comprised by amino acids no. 190 to 214 of PrP<sup>Sc</sup> or a part thereof, more preferably to the  
 sequence from about 202 to about 214 of PrP<sup>Sc</sup>, or a part thereof, or to variants obtained by  
 substituting or omitting one or more amino acids with the proviso that the conformational  
 particularity of said region as exhibited by the PrP<sup>Sc</sup> isoform is essentially retained.

20 According to a preferred embodiment the amino acid sequence is

~~Sub. C5 Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr~~

or

25 ~~Sub. C6 Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr~~

~~Seq. ID No 1 shows a part of C-terminal region of the amino acid sequence of the bovine~~  
~~prion polypeptide that is from amino acid no. 180 to no. 219 as identified in the present~~  
~~invention.~~

Thr-Thr-Lys-Gly-Glu-Asn-Phe-Thr-Glu-Thr-Asp-Ile-Lys-Met-Met-Glu-  
 180                                      185                                      190                                      195  
 Arg-Val-Val-Glu-Gln-Met-Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-  
 5                                      200                                      205                                      210  
 Ala-Tyr-Tyr-Gln-Arg-Gly-Ala-Ser  
 215

An antibody as defined here in the present invention shall be capable to differentiate between PrP<sup>Sc</sup> and PrP<sup>C</sup> by selectively binding to a three dimensional conformation provided by the C-terminal part of the PrP<sup>Sc</sup> isoform, which is not present in the PrP<sup>C</sup> form.

The antibody may be polyclonal or monoclonal, while due to cross-reactivity reasons monoclonal antibodies are preferred. Moreover, also fragments of the antibodies are within the meaning of the present antibodies, in particular those fragment binding to the target, such as the F<sub>ab</sub> regions or parts thereof. Based on the respective need the skilled person will be able to design the corresponding fragments.

The term antibodies is meant to also comprise chimeric antibodies, such as humanized antibodies, wherein the constant region is derived from a human source, while the variable region is derived from animal source, such as mice, so as to decrease a response of the treated individual to the agent. Bispecific antibodies are considered in the present invention as well. Bispecific antibodies are immunoglobulins or fragments thereof wherein the two F<sub>ab</sub> fragments are directed to different targets each. Thus, one F<sub>ab</sub> fragment will be directed to the C-terminal part of PrP<sup>Sc</sup> while the other F<sub>ab</sub> fragment may be directed to any target, such as a target to used in an assay.

The antibody may be linked to markers commonly used in the detection of targets, such as a radioactive label, a fluorescent label or a dye. According a preferred embodiment the antibody is the antibody produced by the hybridoma cell line CNCM I-2476, deposited according to the Budapest Treaty with the Pasteur Institute, Paris, France on May 10<sup>th</sup>, 2000.



The above antibodies may be used for the diagnosis and/or treatment of Bovine Spongiform Encephalopathy or Creutzfeld-Jacobs-Disease or variant form thereof or TSE related diseases in mammals, such as e.g. ungulates or humans, in that the antibody selectively binds to the PrP<sup>Sc</sup> isoform. This trait of being capable to use the present antibodies in different species, e.g. human, cow, sheep etc. is a novel and intriguing feature of the present antibodies and alleviates the determination methods, such that only one antibody is required to investigate all respective individuals.

For determining whether an individual is affected by the corresponding disease a specimen is taken from the individual to be tested, such as a tissue (homogenisate or sections) or a body fluid, e.g. blood, saliva urine or cerebrospinal fluid, and is examined for the presence of the PrP<sup>Sc</sup> isoform, by contacting the specimen under suitable conditions with the antibody.

The method for contacting the specimen with the antibody is not subject to any particular restriction and will be dependent only on the means available and the specimen itself. Hence, the antibodies may be used e.g. in the methods of ELISA, Dot Blot, Western Blot, immunohistochemistry methods and others, all of which the skilled person is well acquainted with.

In order to enable a rapid testing of an individual for the presence of a prion associated disease the present invention also provides for a kit, which comprises at least one antibody according to the present invention. In addition, the kit will also comprise buffers, support material and marker agents adapted to the respective assays performed.

Further, the antibodies of the present invention may also be used in the therapy of prion associated diseases by administering to an affected individual an effective amount of an antibody of the present invention, optionally together with suitable excipients and carriers. Consequently, the present invention will also comprise a pharmaceutical composition containing at least one antibody according to the present invention.

Moreover, the present invention also provides for a method for immunizing an individual against the PrP<sup>Sc</sup> isoform. In this respect peptides of the C-terminal part found to be different from the normal form (PrP<sup>C</sup>) may be used for eliciting an immune response in an individual, which peptides are preferably derived from the prion sequence amino acid no. 190 to 215 or a part thereof, more preferably from the sequence from about 202 to about 214 of the polypeptide, or a part thereof, or from variants obtained by substituting or omitting one or more amino acids with the proviso that the conformational particularity of said region as exhibited by the PrP<sup>Sc</sup> isoform is essentially retained. According to most preferred embodiment the amino acid sequence is

Sub.C8 ~~Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-~~

or

Sub.C9 ~~Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-~~

In addition the antibodies itself may be used to produce antiidiotypic antibodies, which may be used for immunization. It will be appreciated that for the immunization the skilled person will choose the appropriate time frame between the boosting steps and will select an proper adjuvant if deemed necessary.

The present antibodies may also be used for raising anti-idiotypic antibodies, i.e. antibodies that are directed to the binding region of the antibodies of the present invention. These anti-idiotypic antibodies represent a mirror-image of the antibodies of the present invention and may be used for the prevention and therapy of the above mentioned diseases. The anti-idiotypic antibodies are therefore also within the scope of the present invention and may be produced according to methods well known in the art, i.e. by immunizing animals with e.g. the hypervariable region of the antibodies of the present invention and producing polyclonal or monoclonal antibodies against it. In a next step the antibodies obtained will be selected according to the binding of the present antibodies to said anti-idiotypic antibodies.

The method for obtaining the antibodies of the present invention comprises the step of immunizing an animal, such as e.g. mice or rabbit with an immunizing amount of a peptide comprising the amino acids of the C-terminal part of the prion polypeptide, preferably a peptide having the following a sequence :

5

*Sub. C10* ~~—Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr—~~

More preferably, for the immunization step a peptide is used that had been derived from the above sequence by replacing the Gln residue at location no. 207 of the prion polypeptide by Glu to obtain the following amino acid sequence:

10

*Sub. C11* ~~—Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr—~~

This sequence has surprisingly proven to elicit an immune response sufficiently strong to be capable to easily raise antibodies specifically against PrP<sup>Sc</sup>. Without being bound to any theory the surprising result obtained with this peptide may reside in that the native Gln residue may form hydrogen bonds and may such cause insolubility of the peptide, which is not desired when being part of an epitope. On the other hand Glu, which is in the sequence of the human PrP, whereas Gln is at the same position in the primary structure of bovine PrP, seemingly does not form such links.

20

Using any of the above peptides for the immunization step harbors the advantage that no knock out mice have to be prepared in before, such as when using the entire prion polypeptide. For the immunization preferably a conjugate of the peptide and a carrier is used, wherein the peptide is bound to the carrier via its N-terminus. It could be shown that this measure obviously provides for a better immune response as compared to binding the peptide to the carrier via the C-terminus.

25

After immunizing animals with the antigen spleenocytes are isolated and fused with myeloma cells according to methods and techniques well known in the art. Selection for fused cells is performed using an appropriate medium, which does not support growth of

30

unfused cells, such as the HAT medium. Fused myeloma cells growing in the selection medium are screened for the production of antibodies capable to bind to the peptide used for the immunization step.

- 5 The present invention also pertains to hybridoma cell lines capable of producing the antibodies of the present invention and obtainable according to the above method. The lines obtained were found to grow extremely fast, with a doubling time period of about 8 hours. Also the secretion of antibodies was found to be very high as compared to normal hybridoma antibody secretion. According to a preferred embodiment the hybridoma is CNCM I-2476  
10 which has been deposited with the Institute Pasteur, Paris, France on May 10<sup>th</sup>, 2000 according to the Budapest Treaty.

According to another embodiment the present invention relates to a peptide sequence as shown by the following amino acid sequences:

5 ~~Sub C12 Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr~~

or

20 ~~Sub C13 Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr~~


or peptides derived from these sequences by substituting or omitting one or more amino acids with the proviso that the three conformational structure is essentially maintained.

- 25 These peptides obviously provide for a three dimensional conformation exhibited exclusively by the PrP<sup>Sc</sup> isoform and not from the PrP<sup>C</sup> form. Thus, as mentioned above this peptide may well be used for immunizing humans or animals, so that the immunized individual may produce an immune response against the "misfolded form" of the prion polypeptide and depleting it from the body in a natural way. In addition, said polypeptide may also be used  
30 for producing drugs against the above mentioned prion associated diseases.

The following examples illustrate the invention without limiting it to the same.

Example 1**Preparation of a synthetic peptide**

- 5 For the immunization a 13-amino acid long peptide from the primary structure of the human PrP (human prion protein) has been chosen. The peptide is located close to the C-terminal part of the prion protein from amino acid 202 to 214. The peptide has been modified by exchanging the Gln residue at location 207 by a Glu residue to result in the following amino acid sequence



This peptide was bound via its N-terminal part to the carrier protein KLH, keyhole limpet hemocyanin, which represents a novel feature of linking potentially immunogenic peptides to a carrier, since normally the peptide is linked via the C-terminus to the carrier.

Example 2**Immunization of animals**

- 20 BALB/c mice were immunized with 0.2 mg KLH-peptide conjugate (prepared according to example 1) per mouse, subcutaneously in Freund's complete adjuvant (CFA) (200µl/mouse). After 14 days mice were again immunized with 0.1 mg of KLH-peptide per mouse in Freund's incomplete adjuvant (IFA), intraperitoneally (200µl/mouse). After two weeks they were inoculated intraperitoneally with 0.2 mg of KLH-peptide per mouse intraperitoneally in
- 25 Freund's incomplete adjuvant once more. Blood was taken from the tail vein 10 days after the last inoculation and the presence of antibodies against the conjugate was determined by indirect ELISA. Plates were coated with KLH, KLH-peptide and free peptide. The binding of mouse antibodies was detected by goat anti-mouse antibodies, conjugated with HRP. The immune response of all mice was surprisingly very high.

30 A final boost was injected intravenously in physiological solution (0.1 mg/mouse in 100 µl).

### Example 3

#### **Production of hybridomas**

5 On day 4 after the booster injection mice were sacrificed and their spleen was removed. Splenocytes were isolated and fused with mouse myeloma cells NS1 (in ratio 10 : 4) using 50% PEG for 3 minutes according to standard techniques (Liddel, J.E., Cryer, A., A practical guide to monoclonal antibodies. John Wiley&Sons, New York, 1991). Cells were washed and resuspended into 96-well microtiter plates in DMEM (Flow, UK), supplemented with 13% FCS (HyClone, USA) (in the following merely designated DMEM) and with feeder layer of mouse thymocytes. The next day HAT DMEM was added into all wells. Supernatants were tested for the presence of specific antibodies after 10-14 days by indirect ELISA. To this end, microtiter plates (Nunc, Denmark) were coated with 5 µg/ml of the peptide or the KLH-peptide conjugate or KLH alone (Bachem, Switzerland) in 50 mM carbonate/bicarbonate buffer pH 9.6 overnight at +4°C. Plates were washed three times with PBS/Tween 20 (Sigma, USA) and blocked for 30 minutes with 1 % BSA (Sigma, USA). After washing with PBS/Tween20 supernatants were added into the wells and incubated for 2 hours at 37°C. Plates were washed three times with PBS/Tween20 and goat anti-mouse immunoglobulins, conjugated with HRP (Sigma, USA) were added into the wells at dilution 20 1 : 5000 in 1 % BSA. After two hours incubation at 37°C plates were washed with PBS/Tween 20 and substrate was added to the wells (ABTS/H<sub>2</sub>O<sub>2</sub>; Sigma, USA). Plates were read at 410 nm. All volumes were 50 µl.

Hybridomas from positive wells were transferred into larger volumes (24-well plates) in HT 25 DMEM medium. The presence of specific antibodies was determined by indirect ELISA again and selected lines were transferred into tissue culture flasks in DMEM. Finally, selected hybridomas were cloned twice by the limiting dilution method and frozen in liquid nitrogen.

30 The lines selected were growing extremely fast in DMEM, i.e. without the need of HT, with

a doubling time period of about 8 hours. Also the secretion of antibodies was found to be very high. One of the clones obtained was submitted to the Pasteur Institute and received the deposit no CNCM I-2476.

#### 5 Example 4

##### **Testing of the antibodies**

10 The reactivity of the monoclonal antibodies with PrP was tested using the supernatants of the stored clones. The monoclonal antibodies were tested by immuno-histochemistry on brain tissue from CJD patients, vCJD patients and on brains of BSE positive cattle and scrapie infected brains of sheep. For control normal human, bovine and sheep brains were used. The screening was also done by Western blot and dot blot.

Sample preparation for histochemistry:

15 Paraffin sections of brain tissues derived from different sources (human, bovine and goat) were prepared according to standard techniques (machine: Ventana), wherein sections within 6-8µm thickness were obtained. The samples were treated with HCOOH (fig. 1, 5, 6) or not pretreated at all (fig. 2-4). Subsequently endogenous peroxidase was blocked using a kit provided by (Ventana, USA), the antibodies were applied at a concentration of 4 µg/ml, diluted in Dako S-20 2022 (Dako, USA) and incubated for 20 minutes at 42°C.

Subsequently a biotinylated goat anti-mouse+rabbit was applied (Ventana, USA) and incubated for 20 minutes at 42°C, followed by an incubation with streptavidin HRP (Ventana) for 20 minutes at 42°C, DAB (diamino benzidine) with Cu for 4 minutes.

#### 25 **Results:**

The pattern of the immunohistochemical reactions show that mAb CNCM I-2476 reacts with all known TSE forms from different species (human, bovine, sheep) and is reacting only with the pathological protein. There is no reaction on the brain tissue of healthy individuals and 30 patients with Alzheimer disease.

#### Preparation of brain homogenates:

Brain tissue (thalamus or medulla or spinal cord) was homogenized in 10% sucrose, 20 mM HEPES pH 7.5, 2 % sarcosyl and 5 mM EDTA with homogenizer (Potter) (5-times, 0.1 g in 1 ml). Homogenates were centrifuged for 45 minutes at +4°C and 14 000 rpm. The supernatant was frozen at -20°C, whereas the pellet was dissolved in 1 M NaOH. The protein concentration in samples was determined by measuring absorbance at 280 and 260 nm.

#### Dot Blot:

10-times diluted supernatants or pellets were used as samples. They were used either native or digested with proteinase K (10 µg/ml and 100 µg/ml). Electrophoresis was done in Bio Rad cell with 25 mM Tris, 0.32 M glycine, 0.16% SDS (w/v) pH 8.3. The transfer was performed with 25 mM Tris, 192 mM glycine, 20% methanol (v/v), pH 8.3 on 0.2 mm PVDF membrane. Transfer was effected during 50 minutes at 100 V. The membranes were then blocked with 5 % milk and incubated with monoclonal antibodies (for CNM I-2476 40 µg/ml) in 1 % milk for 1-2 hours (gentle shaking). After washing of the membranes they were incubated with secondary antibodies, conjugated with HRP (goat anti-mouse, Sigma, USA), diluted 1 : 5000 in 1 % milk (1-2 hours, gentle shaking). Membranes were washed and immune reaction was detected using chemiluminescence kit (ECL, Amersham, USA).

#### Results:

No reaction of normal brain samples with antibody V5B2 (CNM I-2476) occurred. As positive controls the KLH-peptide was used.

The monoclonal antibodies provided by the present invention show a high specificity for PrP<sup>Sc</sup>. For recognition it was not required to use proteinase K digestion of PrP<sup>C</sup> prior to the screening method. There was no reaction between the normal brain tissues and the mAb under the same conditions, indicating that the produced antibodies are very specific and recognize exclusively PrP<sup>Sc</sup>.